

BlueBox Asset Management launches “Precision Medicine” fund, a focused biotech UCITS fund managed by former Norges portfolio manager Mark Dainty

Geneva, February 28, 2023 – BlueBox Asset Management is proud to announce the launch of its second UCITS fund, the BlueBox Precision Medicine Fund. This is an important milestone in the growth of BlueBox as we fulfil our vision of offering our clients the best long-term thematic investment funds.

The fund will target biotechnology and life science companies that develop, sell or enable Precision Medicine using deep fundamental analysis and a long-term investment horizon.

“We are convinced that precision medicine will shape the future of healthcare as it has exciting applications that improve the patients’ outcome with greater benefit for society. We, at BlueBox, want to offer our investors the opportunity to be part of the transformation and benefit from this long-term megatrend.” - Gely Solis, Director

“Five years after our first, highly successful fund started, we are now launching the Precision Medicine Fund. As a boutique asset manager focused only on our strongest investment convictions, we will only launch a new fund if the opportunity combines a stellar Portfolio Manager with a winning investment strategy, and we found this opportunity with Mark Dainty. Using Mark’s own words, investing in tomorrow’s medicine today is a unique and outperforming investment strategy managed by one of the best. Having Mark as part of the BlueBox investment team puts BlueBox in the top league of boutique asset managers.” - Luis Viveros, Managing Director

Mark joined BlueBox in August 2022 and was previously managing the biotech portfolio at Norges, the Norwegian Sovereign Wealth Fund. Prior to Norges, Mark was part of the global equities team at BlackRock where he worked alongside BlueBox co-founder and technology portfolio manager William de Gale. He has 16 years financial markets experience, all covering the healthcare sector. He holds a master's in pharmacy and is a chartered accountant.

BlueBox Asset Management launches “Precision Medicine” fund, a focused biotech UCITS fund managed by former Norges portfolio manager Mark Dainty

“I enjoyed working with Mark at BlackRock and have great respect for him as an investor, so a couple of years ago I was very interested to hear about his plans to launch his own fund. However, when he described his Precision Medicine approach, the parallels to our existing Direct Connection strategy in the IT sector were so striking that I immediately asked him whether he might be persuaded to launch it at BlueBox. At the time I thought Precision Medicine would be an interesting niche product, but I've since realised that this revolution in how medical treatments are developed, tested and deployed is so vital to the future of our society that Precision Medicine is likely in time to outgrow even the Technology sector. To have an investor of Mark's calibre and experience creating his Precision Medicine fund at BlueBox is an opportunity we simply could not pass up, and we are already seeing cross-fertilisation of ideas between the two strategies.” - William de Gale, BlueBox Global Technology Fund Portfolio Manager

“I am delighted to be launching this fund with the excellent team at BlueBox. We share values, experience and vision making it a natural fit. More than 25 years ago I experienced the first spark that ignited an insatiable curiosity in medicine. The opportunity to invest in biotechnology and life sciences in the era of Precision Medicine, at BlueBox, on behalf of our clients, is an absolute privilege.” - Mark Dainty, BlueBox Precision Medicine Fund Portfolio Manager

BlueBox Asset Management was formed in 2017 when Luis Viveros and Gely Solis, respectively CEO and Head of Investments of BlueBox Wealth Management, partnered with William de Gale, previously the long-time portfolio manager of BlackRock's World Technology Fund, to launch a continuation of his highly successful investment strategy in 2018, focusing on the Direct Connection of technology to the real world: the BlueBox Global Technology Fund. As a boutique Asset Manager, BlueBox is committed to providing investors with funds that combine a traditional investment approach in long-term thematic with enduring growth.

The BlueBox Precision Medicine Fund is a UCITS fund operating under CSSF supervision as a sub-fund to the BlueBox Funds SICAV and comes with daily liquidity.

Contact

marketing@blueboxam.com

www.blueboxfunds.com

All information provided here are subject to change without notice. All investors must obtain and carefully read the prospectus which contains additional information needed to evaluate the potential investment and provides important disclosures regarding risks, fees and expenses. Historical performance is not an indication of current or future performance. Performance shown does not take account of any fees and costs charged when subscribing or redeeming shares. Data and graphical information herein are for information only. No separate verification has been made as to the accuracy or completeness of these data which may have been derived from third party sources. As a result, no representation or warranty, express or implied, is or will be made by BLUEBOX FUNDS as regards the information contained herein. The information contain in this document is not intended for retail investors. It is only available for well informed investors, qualified investors or professional investors.